The pharmaceutical supply chain has never been more strategically important or more politically contested. COVID-19 exposed critical vulnerabilities in the geographic concentration of active pharmaceutical ingredient manufacturing in China and India. The ten leading pharmaceutical companies collectively announced more than $150 billion in U.S. manufacturing investments in 2025 — driven by supply chain resilience imperatives, IRA incentives for domestic manufacturing, and tariff threat responses. The CDMO landscape is being restructured as Samsung Biologics, Lonza, Catalent, and WuXi Biologics collectively provide biologics manufacturing capacity accessed through partnerships.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• API Supply Chain Risk
• Reshoring and Domestic Manufacturing Investment
• CDMO Landscape
• Biologics Manufacturing
• Cell and Gene Therapy Manufacturing
• Tariff and Trade Policy
Table of Contents
1. Executive Summary
2. Market Overview
3. API Supply Chain Risk
4. Reshoring and Domestic Manufacturing Investment
5. CDMO Landscape
6. Biologics Manufacturing
7. Cell and Gene Therapy Manufacturing
8. Tariff and Trade Policy
9. Competitive Landscape
10. Regional Market Analysis
11. Strategic Conclusions and Recommendations
12. Appendix
List of Tables
Table 1. Market Overview 2025
Table 2-8. Topic-Specific Analysis Tables
Table 2. Leading Companies — Portfolio and Strategy Assessment 2025
Table 3. M&A and Partnership Activity 2023-2025
Table 4. Regional Analysis
Table 5. Key Risks and Mitigation Strategies
Companies Profiled
Pfizer
Johnson & Johnson
Roche
Novartis
Merck
AstraZeneca
Bristol-Myers Squibb
AbbVie
Eli Lilly
Sanofi
